Connie Lee Batlevi
0000-0002-9036-9463
Publication & Citation Trends
Publications
0 total
FIVE‐YEAR ANALYSIS OF AN ASIA SUBPOPULATION WITH PREVIOUSLY UNTREATED DLBCL CONFIRMS POLA‐R‐CHP BENEFIT ON OUTCOMES: THE POLARIX STUDY
Cited by 0
Semantic Scholar
Outcomes of tafasitamab and lenalidomide in large B‐cell lymphoma based on prior CD19‐directed CAR T exposure
Cited by 1
Semantic Scholar
ORAL ABSTRACT: ABCL-1492 Mosunetuzumab Plus Polatuzumab Vedotin (M-Pola) is Superior to Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Autologous Stem Cell Transplant (ASCT)-Ineligible Patients With Relapsed/Refractory (R/R) Large B-cell Lymphoma (LBCL): Primary Results of the Phase 3 SUNMO
Cited by 0
Semantic Scholar
Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetration
Cited by 0
Semantic Scholar
Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study
Cited by 0
Semantic Scholar
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial
Cited by 7
Semantic Scholar
Improvements in health-related quality of life (HRQoL) in the SUNMO study: Subcutaneous (SC) mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) vs rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least one prior therap
Cited by 0
Semantic Scholar
ABCL-475: 5-Year Analysis of the POLARIX Study: Prolonged Follow-Up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes
Cited by 0
Semantic Scholar
Assessment of the prognostic value of FDG PET-derived markers and responses in POLARIX
Cited by 0
Semantic Scholar
POSTER: ABCL-1492 Mosunetuzumab Plus Polatuzumab Vedotin (M-Pola) is Superior to Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Autologous Stem Cell Transplant (ASCT)-Ineligible Patients With Relapsed/Refractory (R/R) Large B-cell Lymphoma (LBCL): Primary Results of the Phase 3 SUNMO Trial
Cited by 0
Semantic Scholar
Research Topics
Lymphoma Diagnosis and Treatment
(170)
CAR-T cell therapy research
(83)
Chronic Lymphocytic Leukemia Research
(73)
Viral-associated cancers and disorders
(24)
Cancer Genomics and Diagnostics
(24)
Affiliations
Roche (Switzerland)
Memorial Sloan Kettering Cancer Center
Cornell University
Kettering University
Acentech (United States)